Breaking News, Collaborations & Alliances

ProBioGen Closes Master Service Agreement with NextPoint

Initiates development and GMP manufacturing of NextPoint’s lead antibody candidate.

ProBioGen has closed a Master Service Agreement with NextPoint and initiated development and GMP manufacturing of their lead antibody candidate.
 
ProBioGen’s CHO.RiGHT cell line development including its latest DirectedLuck transposase and platform processes enable the development to provide a high-expressing stable cell line and a robust manufacturing process. Further, ProBioGen’s proprietary cell culture medium makes manufacturing processes even more robust, with improved protein titers and cell growth behavior. The integrated services ensure that NextPoint can bring its molecule to the clinic in a timely manner.
 
“We are proud NextPoint has selected us for this fast track CMC development and manufacturing of its unique antibody that targets a novel immune checkpoint axis offering promise for hard to treat cancers. We are thrilled to support them with our expertise and technology to move this candidate towards the clinic,” says Dr. Gabriele Schneider, chief business offer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters